Discover the top 25 companies transforming the AI in clinical trials market, including IQVIA Inc., Dassault Systèmes (Medidata), Insilico Medicine, and other industry leaders. Backed by a market projected to grow from $1.35B to $2.74B by 2030 at a CAGR of 12.4%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top AI in Clinical Trials Companies

IQVIA Inc.

IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Formed from the merger of IMS Health and Quintiles, the company leverages its massive IQVIA Connected Intelligence platform to integrate unparalleled data, healthcare-grade AI, and deep domain expertise. By connecting over 1.2 billion non-identified patient records and utilizing advanced analytics, IQVIA enables biopharmaceutical companies to accelerate drug development, optimize commercial performance, and improve patient outcomes across more than 100 countries.

Dassault Systèmes (Medidata)

Medidata, a subsidiary of Dassault Systèmes, is the global leader in providing end-to-end cloud-based solutions for the clinical trial process. Its flagship Medidata Rave Clinical Cloud platform serves as a unified ecosystem for clinical data management, electronic data capture, and trial operations. Medidata’s suite of tools, enhanced by AI and advanced analytics through Acorn AI, helps life science companies reduce trial timelines and costs while improving data quality. Supporting thousands of trials and millions of patients, Medidata is a pivotal force in the digital transformation of clinical R&D.

Insilico Medicine

Insilico Medicine is a clinical-stage end-to-end artificial intelligence-driven drug discovery company that utilizes next-generation AI platforms to accelerate pharmaceutical research. The company integrates generative biology and chemistry with deep learning to identify novel disease targets and design innovative molecular structures. By automating the drug discovery process, Insilico Medicine aims to significantly reduce the time and high costs associated with traditional R&D, positioning itself as a transformative player in the development of therapies for cancer, fibrosis, and age-related diseases.

Tempus AI, Inc.

Tempus AI is a technology leader dedicated to advancing precision medicine through the practical application of artificial intelligence in healthcare. The company has built one of the world’s largest libraries of clinical and molecular data, which it uses to provide physicians with actionable insights for personalized patient care. Through its AI-enabled platform, Tempus supports genomic profiling, data licensing, and clinical trial matching, helping life sciences partners establish more efficient therapeutic development pathways and deliver targeted therapies to patients.

Nvidia Corporation

Nvidia Corporation is a global technology giant whose advanced computing hardware and AI software platforms are fundamental to the growth of AI in clinical trials. By providing the high-performance GPUs and specialized frameworks like Nvidia Clara, the company enables researchers to process vast datasets for drug discovery, medical imaging, and genomic analysis with unprecedented speed. Nvidia’s strategic collaborations with biopharma and healthcare providers drive innovation in digital twins and generative AI models, cementing its role as a key infrastructure provider for the next generation of clinical research.

Saama

Saama is a premier AI-driven data analytics company that specializes in transforming life sciences through its advanced clinical data platforms. The company’s solutions, such as the Smart Data Query (SDQ), automate complex data cleaning and validation processes, reducing cycle times from weeks to hours. By providing real-time insights and enhancing data integration across the clinical development continuum, Saama empowers sponsors to make faster, data-driven decisions, ultimately accelerating the delivery of new treatments to market.

Phesi

Phesi is a global leader in patient-centric data analytics, utilizing AI to revolutionize clinical trial design and execution. The company’s Trial Accelerator platform leverages a massive database covering over 100 million patient records and 4,000 indications to provide highly accurate predictive modeling. By simulating clinical trials and optimizing site selection, Phesi helps pharmaceutical companies reduce patient recruitment timelines and eliminate trial design flaws, leading to more efficient and successful clinical programs.

PathAI, Inc.

PathAI is a leading provider of AI-powered pathology solutions designed to improve the accuracy of diagnosis and the efficacy of drug development. The company’s platform utilizes machine learning to analyze tissue samples with high precision, identifying complex biomarkers that are critical for patient stratification in clinical trials. PathAI collaborates with top biopharmaceutical companies to enhance the quality of pathology data, supporting the development of personalized medicines and more reliable clinical trial endpoints.

Unlearn.ai, Inc.

Unlearn.ai is at the forefront of clinical trial innovation, utilizing generative AI to create “Digital Twins” of trial participants. By using these highly accurate machine learning models to simulate patient disease progression, Unlearn allows sponsors to run smaller, faster, and more ethically sound clinical trials with fewer patients in placebo groups. This groundbreaking approach reduces costs and accelerates the regulatory approval process, particularly in complex therapeutic areas like Alzheimer’s and other neurodegenerative diseases.

Deep6.ai

Deep6.ai is a specialized AI company that accelerates clinical trial recruitment by utilizing natural language processing (NLP) to analyze unstructured medical data within electronic health records. Its platform allows researchers to find eligible patients for complex trials in real-time, often reducing the identification process from months to minutes. By connecting life sciences companies with clinical sites through a high-precision matching engine, Deep6.ai helps solve one of the most significant bottlenecks in clinical research.

Microsoft

Microsoft is a major provider of cloud infrastructure and AI services that support the global clinical trial ecosystem through its Azure platform. By offering secure, compliant, and scalable cloud computing, Microsoft enables life sciences companies to manage vast datasets and deploy sophisticated AI models for drug discovery and trial management. Through strategic partnerships and AI-driven productivity tools, Microsoft empowers organizations to enhance collaboration, improve operational efficiency, and drive innovation in healthcare R&D.

IBM

IBM is a pioneer in the application of artificial intelligence and cognitive computing in the healthcare and life sciences sectors. Through its advanced AI capabilities and consulting services, IBM helps organizations manage complex clinical trial data, optimize protocols, and enhance regulatory compliance. The company’s focus on hybrid cloud and AI-driven automation provides biopharmaceutical companies with the tools needed to integrate disparate data sources and gain deeper insights into patient populations and therapeutic efficacy.

ConcertAI

ConcertAI is a leader in high-quality real-world data (RWD) and AI technology solutions for life sciences and healthcare. The company specializes in oncology and other complex diseases, providing integrated AI platforms that accelerate clinical research and evidence generation. By bridging the gap between clinical practice and clinical trials, ConcertAI enables researchers to design better studies, identify underserved patient populations, and gain a more comprehensive understanding of drug performance in real-world settings.

AiCure

AiCure is an AI and advanced data analytics company that uses computer vision and deep learning to monitor patient behavior and medication adherence in clinical trials. Its platform utilizes mobile devices to confirm that participants are taking their medication correctly and to capture digital biomarkers that provide insights into patient health. By ensuring high-quality data and improving participant engagement, AiCure helps sponsors reduce trial risks and improve the accuracy of clinical results.

Median Technologies

Median Technologies is a leading provider of AI-powered imaging solutions and clinical trial services, specializing in the analysis of medical images to monitor patient response to treatment. Its iBiopsy and iCRO platforms leverage advanced algorithms to extract non-invasive biomarkers from CT, MRI, and PET scans, providing critical data for oncology trials and other therapeutic areas. Median’s technology supports early disease detection and precise quantification of treatment efficacy, enhancing the success rate of clinical development programs.

Lantern Pharma Inc.

Lantern Pharma is a clinical-stage biotechnology company that integrates artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its proprietary RADR platform analyzes billions of data points to identify patients who are most likely to respond to specific oncology therapies and to rescue stalled drug candidates. By using AI to guide clinical trial design and patient selection, Lantern Pharma aims to significantly reduce the time, risk, and cost of bringing life-saving cancer treatments to patients.

Citeline, a Norstella Company

Citeline, part of the Norstella group, provides comprehensive business intelligence and data solutions for the global pharmaceutical industry. Its AI-driven platforms, including Pharmaprojects and Trialtrove, offer unparalleled insights into the clinical trial landscape, drug pipelines, and investigator performance. By delivering integrated data and analytics across the entire drug lifecycle, Citeline empowers life sciences companies to make informed strategic decisions regarding portfolio management, clinical trial design, and commercialization.

TriNetX, LLC

TriNetX is a global health research network that optimizes clinical trial design and patient recruitment through a massive federated data platform. By providing researchers with real-time access to de-identified EHR data from healthcare organizations worldwide, TriNetX enables sponsors to assess trial feasibility and identify eligible patient cohorts with high precision. The company’s AI-powered analytics help biopharmaceutical companies accelerate trial timelines, improve site selection, and generate real-world evidence to support regulatory submissions.

ReviveMed Inc.

ReviveMed is a pioneer in the application of AI for metabolomics-driven drug discovery and development. The company’s platform integrates large-scale metabolomics data with other “omics” datasets to identify novel therapeutic targets and biomarkers. By using machine learning to understand the metabolic signatures of diseases, ReviveMed helps life sciences companies discover new treatments and develop precision medicine approaches, particularly for complex metabolic and inflammatory conditions.

Euretos

Euretos provides an innovative AI-driven platform for target discovery and translational research, integrating a vast array of biological and clinical data. The company’s Knowledge Platform enables researchers to uncover hidden connections between genes, proteins, diseases, and drugs, facilitating the identification of novel therapeutic targets. By providing a comprehensive, multi-omics view of disease biology, Euretos supports biopharmaceutical companies in making more informed decisions during the early stages of drug development and clinical trial planning.

VeriSIM Life

VeriSIM Life is an AI-technology company that accelerates the development of new drugs by predicting clinical success in the early stages of research. Its BIOiSIM platform uses hybrid machine learning and mechanistic modeling to simulate how drugs will behave in human systems, reducing the need for extensive animal testing. By providing high-fidelity predictions of drug efficacy and safety, VeriSIM Life helps pharmaceutical companies optimize their lead candidates and de-risk the transition from pre-clinical studies to clinical trials.

Triomics

Triomics is a specialized AI company focused on streamlining clinical trial workflows for oncology centers and life sciences sponsors. The company utilizes advanced large language models (LLMs) to automate the curation of complex clinical data and to match patients with precision oncology trials. By reducing the administrative burden on clinical staff and improving the speed of patient identification, Triomics helps healthcare institutions increase trial enrollment and allows patients to access innovative treatments more quickly.

Ardigen

Ardigen is a bioinformatics and AI company that supports the life sciences industry through the application of advanced data science to immunology and oncology. The company’s platforms utilize machine learning to design personalized vaccines and therapies, as well as to identify predictive biomarkers for immunotherapy response. Ardigen’s expertise in digital pathology and “omics” data analysis helps biopharmaceutical partners accelerate the discovery of targeted treatments and optimize the design of precision medicine clinical trials.

QuantHealth Ltd.

QuantHealth is an AI-driven clinical simulation company that predicts the outcome of clinical trials with high accuracy before they are even conducted. Its platform leverages a massive database of clinical and pharmacological data to simulate thousands of trial scenarios, helping sponsors optimize protocol design and patient inclusion criteria. By identifying potential failure points and predicting efficacy across different patient subpopulations, QuantHealth enables pharmaceutical companies to maximize the success rate of their clinical programs and reduce R&D waste.

Deep Genomics

Deep Genomics is a leading AI-biotech company that integrates artificial intelligence and genomics to discover and develop genetic medicines. The company’s AI platform, AI Workbench, analyzes how genetic variations affect cell biology to identify novel drug targets and design antisense oligonucleotide therapies. By using AI to navigate the complexity of the human genome, Deep Genomics aims to transform the treatment of rare and complex genetic diseases, significantly accelerating the path from target identification to clinical evaluation.

Download PDF Brochure:“Click Here”